Showing posts with label Pharmaceutical Company. Show all posts
Showing posts with label Pharmaceutical Company. Show all posts
Thursday
OxyContin Maker Negotiates $12B Settlement
Purdue Pharma and the thousands of state and local governments suing the maker of OxyContin over the nation’s deadly opioid crisis are negotiating a $10 billion to $12 billion settlement under which the Sackler family would give up ownership of the company, according to published reports.
Under the proposal now on the table, the Sacklers would contribute $3 billion of their own money toward the total, and the company would file for Chapter 11 bankruptcy and transform itself into a “public beneficiary trust,” with all profits from drug sales going to the plaintiffs, The New York Times reported Wednesday. It said a document outlining the tentative agreement was described to the newspaper.
Also, Purdue Pharma would supply its addiction treatment drugs free to the public, and the Sacklers would sell another pharmaceutical company, Mundipharma, which would add $1.5 billion to the settlement, the Times said.
In a statement, the Stamford, Connecticut-based company did not confirm any of the details — some of them also reported by NBC — but said it sees little good in years of “wasteful litigation and appeals.”
“Purdue believes a constructive global resolution is the best path forward, and the company is actively working with the state attorneys general and other plaintiffs to achieve this outcome,” it said.
Paul Farrell Jr., a lead plaintiffs’ lawyer representing local governments, said all sides remain under a gag order:
“All we can confirm is that we are inactive settlement discussions with Purdue.”
Attorneys general representing several states also confirmed the accelerated negotiations.
“Our mission here has always been clear — make Purdue Pharma and the other manufacturers and distributors pay for what they did to Pennsylvania and its people, and put the Sackler family out of the opioid business for good,” said Jacklin Rhoads, spokeswoman for Pennsylvania Attorney General Josh Shapiro, whose office is taking part in the Cleveland negotiations.
The settlement talks involve more than 2,000 lawsuits against the company and other players in the painkiller industry over the opioid overdose epidemic that has killed more than 400,000 people in the U.S. since 2000 and torn apart communities.
The first federal trial over the devastating toll is scheduled to start in Cleveland in two months.
Purdue has been cast by attorneys and addiction experts as a chief villain in the crisis.
While its painkillers represent a very small piece of the opioid market, the lawsuits accuse it of playing a central role in creating demand for the drugs by downplaying OxyContin’s addiction risks and pushing doctors hard to prescribe it.
New York Attorney General Letitia James said in a statement that the Sackler family “started a national fire” and has “made billions profiting from death and destruction.”
The Sacklers were ranked America’s 19th-richest family by Forbes magazine in 2016, with a net worth estimated at $13 billion.
In March, Purdue and the Sackler family reached a $270 million settlement with Oklahoma over the opioid scourge.
On Monday, an Oklahoma judge found Johnson & Johnson responsible for fueling the state’s opioid crisis and ordered the maker of such familiar household products as Band-Aids and baby powder to pay $572 million to help clean up the problem.
It was the first opioid lawsuit brought against the industry by a state to go to trial, and activists expressed hope the verdict would turn up the pressure on other companies to settle.
Members of the Sackler family are major philanthropists who have given money to cultural institutions around the world, including the Smithsonian Institution, New York City’s Metropolitan Museum of Art and London’s Tate Modern. But in recent months, institutions have come under pressure to sever ties to the Sacklers and take the family name off their walls.
source: usa.inquirer.net
Tuesday
Bayer wins Merck & Co's $14 billion consumer unit auction
Germany's Bayer AG has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare industry.
"This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business," Bayer's chief executive Marijn Dekkers said in a statement on Tuesday.
Merck said it expects after-tax proceeds of between $8 billion and $9 billion from the sale, which is expected to close in the second half of 2014.
The transaction, the largest in the German healthcare industry since Bayer bought rival Schering in 2006, will make Bayer the second biggest over-the-counter drugs maker after Johnson & Johnson, as it seeks to make better use of its distribution network and sales force.
"We can take these products and market them more forcefully than Merck has been able to do so far," Dekkers said in a conference call with analysts.
Bayer, the inventor of aspirin and maker of Bepanthen skin care products and Canesten antifungal creams, has repeatedly said it wants to overtake J&J in the rankings.
Drug makers have embarked on a major reshuffling of their business portfolios. Novartis and GlaxoSmithKline (GSK) last month agreed to trade more than $20 billion worth of assets, while AstraZeneca is fighting off a $106 billion takeover approach from Pfizer.
Meanwhile companies including France's Sanofi, Merck & Co and Abbott are looking at selling off mature drugs that have lost patent protection.
OTC drugs units carry far lower margins than prescription drugs businesses but many drug majors regard them as attractive complements due to the stable stream of cash they can generate.
They akso require less spending on research and development and can be less exposed to the loss of patent protection where consumers remain loyal to a brand even when cheap copies become available.
But Reckitt Benckiser Group, one of the final contenders in Merck's auction, said on April 30 it was no longer in active talks to buy the Merck business, leaving Bayer in pole position.
Bayer also edged out other rival bidders, including Procter & Gamble Co, Boehringer Ingelheim, Novartis and Sanofi , people familiar with the matter have said.
J&J commands about 4 percent of the consumer health market - worth nearly $200 billion at the retail level.
Merck & Co has around 1 percent with brands including Dr Scholl foot care, Coppertone sunscreen and Claritin allergy medicine.
The fragmented OTC industry is consolidating fast. Novartis and GSK will form a joint venture in consumer healthcare as part of their agreement last month.
That deal would have relegated Bayer from second to third place in the global OTC rankings but the Merck deal will put it back on the second rung.
Reuters first reported last month that Bayer and Reckitt had
emerged as frontrunners in the auction with each initially offering roughly $13.5 billion.
In addition, Bayer agreed to sell to Merck some rights to its Adempas drug against high blood pressure in the lung and other experimental cardiovascular drugs, saying it needed a marketing partner.
As part of that alliance, Merck will pay up to $2.1 billion, including $1.1 billion in milestone payments contingent on development achievements.
Bayer said it plans to finance the OTC acquisition with a bridge loan facility provided by Bank of America Merrill Lynch, BNP Paribas and Mizuho, which will be syndicated to a larger group of banks.
It added no asset sales were needed to preserve its credit rating of "A-". — Reuters
source: gmanetwork.com
Labels:
Bayer,
Bayer AG,
Business,
Healthcare,
Merck & Co Inc,
Pharmaceutical Company,
World News
Subscribe to:
Posts (Atom)


